Clinical and Translational Oncology

, Volume 20, Issue 10, pp 1329–1336 | Cite as

Dosimetry study of 18F-FMISO + PET/CT hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer

  • H. Li
  • D. Xu
  • X. Han
  • Q. Ruan
  • X. Zhang
  • Y. Mi
  • M. Dong
  • S. Guo
  • Y. Lin
  • B. Wang
  • G. Li
Research Article



This study was to evaluate the feasibility of simultaneous integrated boost on tumor hypoxia area by studying the dosimetric change of hypoxia imaging guidance on intensity-modulated radiation therapy for non-small cell lung cancer (NSCLC).


Five NSCLC patients with large hypoxic volume participated in this study. FDG PET/CT images were fused with CT localization images to delineate gross tumor volume. FMISO PET/CT images were fused with CT localization images to delineate hypoxic biological target volume (BTV) (tissue maximum ratio ≥ 1.3) by threshold. BTV was irradiated with 72, 78 and 84 Gy, respectively, 30 times. The dosimetry differences were compared in target volume and organ at risk between simultaneous integrated boost plans and conventional radiotherapy plans.


Dosages on BTV of NSCLC hypoxic area were increased to 72, 78 and 84 Gy, respectively, by simultaneous integrated boost intensity-modulated radiation therapy. There was no obvious difference in dosage distributions on original target volume compared with those in conventional radiotherapy. Dosages on main organ at risk in chest met the dosimetric constraint, and there was no significant difference compared with those in conventional radiotherapy.


It is feasible in dosiology that the dosages in NSCLC hypoxic area were added to 72, 78 and 84 Gy by simultaneous integrated boost with the guidance of 18F-FMISO PET/CT.


Lung cancer Hypoxia PET Radiotherapy Simultaneous integrated boost FMISO 



This study was supported by Henan Provincial Department of Science, China, 142102310052.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of The First Affiliated Hospital of Zhengzhou University.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefGoogle Scholar
  2. 2.
    Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31(8):992–1001.CrossRefGoogle Scholar
  3. 3.
    Li L, Hu M, Zhu H, Yang G, Yu J. Comparison of 18F-fluoroerythronitroimidazole and 18F-fluorodeoxyglucose positron emission tomography and prognostic value in locally advanced non-small-cell lung cancer. Clin Lung Cancer. 2010;11(5):335–40.CrossRefGoogle Scholar
  4. 4.
    Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955;9(4):539.CrossRefGoogle Scholar
  5. 5.
    Eschmann SM, Paulsen F, Reimold M, Dittmann H, Welz S, Reischl G, et al. Prognostic impact of hypoxia imaging with 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med. 2005;46(2):253–60.PubMedGoogle Scholar
  6. 6.
    Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG—a marker of tumour hypoxia? A comparison with [18F] fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging. 2006;33(12):1426–31.CrossRefGoogle Scholar
  7. 7.
    Gagel B, Reinartz P, Dimartino E, Eble MJ. pO2 polarography versus positron emission tomography ([(18)F] fluoromisonidazole, [(18)F]-2-fluoro-2′-deoxyglucose). An appraisal of radiotherapeutically relevant hypoxia. Strahlenther Onkol. 2004;180(10):616–22.CrossRefGoogle Scholar
  8. 8.
    Bowen SR, Kogel AJVD, Nordsmark M, Bentzen SM, Jeraj R. Characterization of positron emission tomography hypoxia tracer uptake and tissue oxygenation via electrochemical modeling. Nucl Med Biol. 2011;38(6):771–80.CrossRefGoogle Scholar
  9. 9.
    Brustugun OT. Hypoxia as a cause of treatment failure in non-small cell carcinoma of the lung. Semin Radiat Oncol. 2015;25(2):87–92.CrossRefGoogle Scholar
  10. 10.
    Popple RA, Ove R, Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys. 2002;54(3):921–7.CrossRefGoogle Scholar
  11. 11.
    Corvo R, Santoni R, Magrini SM, Maurizi ER. Radiobiology as a basic and clinical medical science: what the physicists have forgotten. Tumori. 2016;102(1):e8.CrossRefGoogle Scholar
  12. 12.
    Henk JM, Smith CW. Radiotherapy and hyperbaric oxygen in head and neck cancer. Interim report of second clinical trial. Lancet. 1977;2(8029):104–5.CrossRefGoogle Scholar
  13. 13.
    Cade IS, McEwen JB, Dische S, Saunders MI, Watson ER, Halnan KE, et al. Hyperbaric oxygen and radiotherapy: a Medical Research Council trial in carcinoma of the bladder. Br J Radiol. 1978;51(611):876–8.CrossRefGoogle Scholar
  14. 14.
    Overgaard J. Clinical evaluation of nitroimidazoles as modifiers of hypoxia in solid tumors. Oncol Res. 1994;6(10–11):509–18.PubMedGoogle Scholar
  15. 15.
    Grau C, Prakash Agarwal J, Jabeen K, Rab Khan A, Abeyakoon S, Hadjieva T, et al. Radiotherapy with or without mitomycin c in the treatment of locally advanced head and neck cancer: results of the IAEA multicentre randomised trial. Radiother Oncol. 2003;67(1):17–26.CrossRefGoogle Scholar
  16. 16.
    Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348(25):2500–7.CrossRefGoogle Scholar
  17. 17.
    Chang JH, Wada M, Anderson NJ, Lim Joon D, Lee ST, Gong SJ, et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18) F-FMISO PET: a biological modeling study. Acta Oncol. 2013;52:1723–9.CrossRefGoogle Scholar
  18. 18.
    Bartlett RM, Beattie BJ, Naryanan M, Georgi JC, Chen Q, Carlin SD, et al. Image-guided pO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats. J Nucl Med. 2012;53:1608–15.CrossRefGoogle Scholar
  19. 19.
    Koch CJ, Giandomenico AR, Iyengar CW. Bioreductive metabolism of AF-2[2-(2-furyl)-3-(5-nitro-2-furyl)acrylamide] combined with 2-nitroimidazoles. Implications for use as hypoxic cell markers. Biochem Pharmacol. 1993;46:1029–36.CrossRefGoogle Scholar
  20. 20.
    Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105:14–20.CrossRefGoogle Scholar
  21. 21.
    Bentzen SM, Gregoire V. Molecular imaging-based dose painting: a novel paradigm for radiation therapy prescription. Semin Radiat Oncol. 2011;21(2):101–10.CrossRefGoogle Scholar
  22. 22.
    Sovik A, Malinen E, Olsen DR. Strategies for biologic image-guided dose escalation: a review. Int J Radiat Oncol Biol Phys. 2009;73(3):650–8.CrossRefGoogle Scholar
  23. 23.
    Christian JA, Bedford JL, Webb S, Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67(3):735–41.CrossRefGoogle Scholar
  24. 24.
    Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2007;68(1):94–102.CrossRefGoogle Scholar
  25. 25.
    Palma DA, Senan S, Oberije C, Belderbos J, de Dios NR, Bradley JD, et al. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2013;87(4):690–6.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  1. 1.Radiotherapy DepartmentThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Nuclear Medicine DepartmentThe First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  3. 3.Radiotherapy DepartmentZhengzhou Central HospitalZhengzhouChina

Personalised recommendations